HomeUSALife Sciences Accelerator Blackbird Labs Launches with $100M

Life Sciences Accelerator Blackbird Labs Launches with $100M

Blackbird Laboratories

Blackbird Laboratories, Inc., a Baltimore, MD-based next-generation life sciences accelerator, launched with a $100m founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins University, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development.

Led by Matt Tremblay, Ph.D., CEO, Blackbird Labs aims to accelerate the development and commercialization of novel medicines and technologies to enhance the well-being of patients facing unmet medical needs.

The accelerator identifies innovative technologies within its partner institutions that require additional experimentation and business ideation in order to be ready for start-up creation and investment by the broader venture capital and biopharma communities.

Blackbird Labs provides capital, program management, and strategic scientific and business input from its team of life sciences professionals, seeking to bridge the gap between pioneering academic science and industry.

Initially, it will be focused on advancing innovation across a wide range of therapeutic modalities and indications, including inflammation and immunology, neurological diseases, genetic diseases, and cancer.

Formerly Chief Operating Officer of The Scripps Research Institute and its drug discovery division, Calibr, Tremblay brings a wealth of experience in early-stage technology research and business strategy. Together with Point Field Partners, the family office of Steve Bisciotti, Tremblay simultaneously created and serves as Managing Director of Wolf Point, LLC, which will provide early-stage venture capital co-investments as part of an integrated approach to fostering the biotechnology start-up ecosystem in Baltimore.

Blackbird Labs has already funded and established a portfolio of collaborations with its partners, including a novel oral therapeutic for Crohn’s and colitis; an RNA-based therapeutic platform targeting mRNA upregulation; a cell type-specific gene therapy platform technology; a multi-modal approach to schizophrenia; and a patient-facing digital platform aimed at accelerating clinical trial enrollment.